/CNW/ - Apotex Inc., Canada s leading pharmaceutical manufacturer of generic medicines, announced today the launch of APO-ApixabanTM tablets, Canada s first.
Share this article
Part of the Critical Drug Reserve in COVID-19 Response
TORONTO, April 15, 2021 /CNW/ - As Canadians remain impacted by the spread of COVID-19, Apotex, Canada s largest pharmaceutical company has been awarded a contract with the Government of Canada to supply the Critical Drug Reserve of Dexamethasone tablets in response to the COVID-19 pandemic.
Dexamethasone is a corticosteroid used in a wide range of conditions for its anti-inflammatory and immunosuppressant effects.
According to the World Health Organization, It was tested in hospitalized patients with COVID-19 in the United Kingdom s national clinical trial RECOVERY and was found to have benefits for critically ill patients. According to preliminary findings shared with WHO (and now available as a preprint), for patients on ventilators, the treatment was shown to reduce mortality by about one third, and for patients requiring only oxygen, mortality was cut by about one fifth.